KRAS and intraepithelial neoplasia: KRAS mutations lead to constitutive activation of the RAS protein, resulting in activation of the RAF/MEK/ERK pathway or PI3K/PDK1/AKT/mTOR pathway and, ultimately, the development of intraepithelial neoplasia [21].